Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...
Choose the hash algorithm you want to use For bcrypt and Argon2id, you'll be prompted for additional parameters The result will be inserted at the cursor position or replace the selected text The ...
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year. 2025 was a slow year for IPOs, with ...
Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...
Generate is indicative of a more mature startup that may have a better chance of succeeding in today’s markets. Industry IPOs peaked in 2021, resulting in a flood of companies whose early science didn ...
President Donald Trump's "big beautiful bill" boosted the SALT deduction limit to $40,000 for 2025, up from the previous $10,000 cap. The SALT deduction includes property taxes plus either state and ...
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Because it's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results